Product Name
MBNL1, siRNA
Full Product Name
MBNL1 siRNA (Human)
Product Synonym Names
EXP; KIAA0428; MBNL; Muscleblind-like protein 1; Triplet-expansion RNA-binding protein
Product Gene Name
MBNL1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9NR56
Specificity
MBNL1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MBNL1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MBNL1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MBNL1 sirna
siRNA to inhibit MBNL1 expression using RNA interference
Applications Tested/Suitable for MBNL1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MBNL1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_066368.2
[Other Products]
NCBI GenBank Nucleotide #
NM_021038.3
[Other Products]
UniProt Primary Accession #
Q9NR56
[Other Products]
UniProt Secondary Accession #
O43311; O43797; Q86UV8; Q86UV9; Q96P92; Q96RE3; E9PBW7[Other Products]
UniProt Related Accession #
Q9NR56[Other Products]
Molecular Weight
36,992 Da
NCBI Official Full Name
muscleblind-like protein 1 isoform a
NCBI Official Synonym Full Names
muscleblind-like splicing regulator 1
NCBI Official Symbol
MBNL1 [Similar Products]
NCBI Official Synonym Symbols
EXP; MBNL; EXP35; EXP40; EXP42
[Similar Products]
NCBI Protein Information
muscleblind-like protein 1
UniProt Protein Name
Muscleblind-like protein 1
UniProt Synonym Protein Names
Triplet-expansion RNA-binding protein
Protein Family
Muscleblind-like protein
UniProt Gene Name
MBNL1 [Similar Products]
UniProt Synonym Gene Names
EXP; KIAA0428; MBNL [Similar Products]
UniProt Entry Name
MBNL1_HUMAN
UniProt Comments for MBNL1
MBNL1: Mediates pre-mRNA alternative splicing regulation. Acts either as activator or repressor of splicing on specific pre-mRNA targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle. Antagonizes the alternative splicing activity pattern of CELF proteins. Regulates the TNNT2 exon 5 skipping through competition with U2AF2. Inhibits the formation of the spliceosome A complex on intron 4 of TNNT2 pre-mRNA. Binds to the stem-loop structure within the polypyrimidine tract of TNNT2 intron 4 during spliceosome assembly. Binds to the 5'-YGCU(U/G)Y- 3'consensus sequence. Binds to the IR RNA. Binds to expanded CUG repeat RNA, which folds into a hairpin structure containing GC base pairs and bulged, unpaired U residues. Plays a role in the pathogenesis of dystrophia myotonica type 1 (DM1). A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias. In muscle cells from DM1 patients, MBNL1 is sequestered by DMPK RNAs containing CUG triplet repeat expansions. MBNL1 binding is proportional to repeat length consistent with the direct correlation between the length of repeat expansion and disease severity. Belongs to the muscleblind family. 6 isoforms of the human protein are produced by alternative splicing.
Protein type: RNA-binding; RNA splicing
Chromosomal Location of Human Ortholog: 3q25
Cellular Component: nucleoplasm; centrosome; stress granule; cytoplasm; nucleus
Molecular Function: protein binding; RNA binding; metal ion binding; double-stranded RNA binding
Biological Process: myoblast differentiation; alternative nuclear mRNA splicing, via spliceosome; mRNA splice site selection; nervous system development; skeletal muscle development; regulation of RNA splicing; in utero embryonic development; RNA splicing; regulation of alternative nuclear mRNA splicing, via spliceosome; embryonic limb morphogenesis
Research Articles on MBNL1
1. Results show that nuclear localization is a major determinant of MBNL1 function. It promotes the nuclear retention of repeat-containing transcripts, which results in repression of aberrant protein expression from the expanded repeats.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
